Payment overview · 2025
General Payments
$793.15
50 reported records · 12 companies
Healthcare provider profile · identity verified
Stephen A Davis, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · MOBILE, AL · NPI 1285675710
Verified facts
What the public records show
CMS Open Payments records show Stephen A Davis, M.D. received $793.15 in general payments during 2025 across 50 reported records.
Novo Nordisk Inc accounted for 28.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 273 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $226.17 | 28.5% | 17 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $191.99 | 24.2% | 12 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $120.13 | 15.2% | 7 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.60 | 5.6% | 2 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $44.13 | 5.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.28 | 5.5% | 3 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $39.67 | 5.0% | 2 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $19.45 | 2.5% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$18.30 | 2.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.34 | 2.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.23 | 1.8% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $13.86 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $793.15 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $226.17 | 17 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $155.29 | 11 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $120.13 | 7 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $84.18 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $78.59 | 6 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $44.60 | 2 | 2025 |
Source payment records
|
|||||
| MYCAPSSA Normalized: mycapssa |
Drug | Chiesi USA, Inc. | $44.13 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $43.28 | 3 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $39.67 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.22 | 2 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $19.45 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $19.45 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $19.45 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $13.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 32 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 273 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 59 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
69 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
32 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
273 | 59 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
59 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 457 | 121 |
| Atorvastatin Calcium | Atorvastatin Calcium | 366 | 103 |
| Losartan Potassium | Losartan Potassium | 363 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 316 | 88 |
| Ozempic | Semaglutide | 273 | 59 |
| Omeprazole | Omeprazole | 266 | 79 |
| Pravastatin Sodium | Pravastatin Sodium | 220 | 70 |
| Metformin Hcl | Metformin Hcl | 217 | 66 |
| Pioglitazone Hcl | Pioglitazone Hcl | 168 | 42 |
| Gabapentin | Gabapentin | 161 | 46 |
| Potassium Chloride | Potassium Chloride | 139 | 41 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 139 | 39 |
| Allopurinol | Allopurinol | 134 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 132 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 129 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 125 | 38 |
| Lisinopril | Lisinopril | 116 | 33 |
| Furosemide | Furosemide | 111 | 34 |
| Trazodone Hcl | Trazodone Hcl | 111 | 34 |
| Simvastatin | Simvastatin | 109 | 35 |
| Lorazepam | Lorazepam | 107 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 91 | 22 |
| Carvedilol | Carvedilol | 89 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 87 | 23 |
| Alprazolam | Alprazolam | 86 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 86 | 25 |
| Mounjaro | Tirzepatide | 85 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 84 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 80 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 78 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 77 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 26 |
| Alendronate Sodium | Alendronate Sodium | 72 | 21 |
| Synthroid | Levothyroxine Sodium | 69 | 14 |
| Sertraline Hcl | Sertraline Hcl | 68 | 19 |
| Glimepiride | Glimepiride | 65 | 20 |
| Tramadol Hcl | Tramadol Hcl | 65 | 22 |
| Meloxicam | Meloxicam | 63 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 25 |
| Metformin Hcl Er | Metformin Hcl | 60 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 59 | 19 |
| Rybelsus | Semaglutide | 59 | 11 |
| Celecoxib | Celecoxib | 55 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 14 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 46 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 46 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 45 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 16 |
| Eliquis | Apixaban | 42 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 42 | 11 |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Verapamil Er | Verapamil Hcl | 36 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 35 | 20 |
| Famotidine | Famotidine | 34 | 13 |
| Montelukast Sodium | Montelukast Sodium | 34 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Jardiance | Empagliflozin | 32 | 11 |
| Terazosin Hcl | Terazosin Hcl | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 24 |
| Tresiba Flextouch U-200 | Insulin Degludec | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 27 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 11 |
| Estradiol | Estradiol | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 14 |
| Spironolactone | Spironolactone | 23 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Humalog | Insulin Lispro | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 15 |
| Temazepam | Temazepam | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Prednisone | Prednisone | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Victoza 2-Pak | Liraglutide | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Bystolic | Nebivolol Hcl | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $793.15 · 50 records | Novo Nordisk Inc | EVENITY, FREESTYLE LIBRE 3, GVOKE HYPOPEN, JARDIANCE, Kerendia, MINIMED 780G, MYCAPSSA, Ozempic, PROLIA, REPATHA, Rybelsus, TEPEZZA, Tymlos, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset, t:slim X2 Insulin Pump with Control-IQ | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error